Highlights Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-05-15 pm EDT			After hours 07:30:37 pm
4.110 ^USD	+7.03%		4.075	-0.85%

May. 15	Myriad Genetics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03:00 PM
May. 08	Myriad Genetics Shares Drop After Downgrade From Wolfe Research	MT

Highlights

Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology	May. 07	CI
Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Earnings Flash (MYGN) Myriad Genetics Posts Q1 Adjusted EPS $-0.03, vs. FactSet Est of $-0.05	May. 06	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $-0.02 - $0.02	May. 06	MT
Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025	May. 06	CI
Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting	Apr. 25	CI
Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing	Apr. 21	CI
Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025	Apr. 07	CI
Myriad Genetics, Inc. Provides Financial Guidance for 2025	Feb. 26	CI
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Underwhelming Economic Data, Renewed Trade Tensions	Feb. 25	MT
Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated	Feb. 25	MT
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 24	CI
Earnings Flash (MYGN) Myriad Genetics, Reports Q4 Revenue $210.6M, vs. FactSet Est of $211.6M	Feb. 24	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $0.07 - $0.11	Feb. 24	MT
(MYGN) Myriad Genetics Forecasts Fiscal Year 2025 Revenue Range $840M - $860M	Feb. 24	MT
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 24	CI
Myriad Genetics, Inc. Partners with PATHOMIQ , Inc. to Add Artificial Intelligence Technology Platform to Its Oncology Portfolio	Feb. 24	CI
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay	Feb. 05	MT
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and Myrisk Hereditary Cancer Test Through Bxlink Integration	Feb. 05	CI
Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance	Jan. 15	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $0.07 - $0.11	Jan. 15	MT
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Revenue Range $840M - $860M	Jan. 15	MT
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025	Jan. 15	CI
Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay	Jan. 07	MT
Top Premarket Decliners	Dec. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Highlights

Filters